We are live on ! Find out more
AC

Aaron Cowen Suvretta Capital Management

AUM $5.47B
1-Year Est. Return 131.34%
 

Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.

This Fund
S&P 500
This Quarter Est. Return
+5.53%
1 Year Est. Return
+131.34%
3 Year Est. Return
+363.85%
5 Year Est. Return
+515.73%
10 Year Est. Return
+2,786.05%
AUM
$6.69B
AUM Growth
-$75.7M
Cap. Flow
-$285M
Cap. Flow %
-4.26%
Top 10 Hldgs %
37.76%
Holding
142
New
36
Increased
36
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$255M
2
META icon
Meta Platforms (Facebook)
META
+$149M
3
TWLO icon
Twilio
TWLO
+$109M
4
CPRT icon
Copart
CPRT
+$103M
5
AAPL icon
Apple
AAPL
+$94.3M

Top Sells

Rank Stock Value
1
MCD icon
McDonald's
MCD
+$214M
2
DG icon
Dollar General
DG
+$212M
3
DIS icon
Walt Disney
DIS
+$212M
4
FIVE icon
Five Below
FIVE
+$147M
5
NKE icon
Nike
NKE
+$143M

Sector Composition

Rank Sector Weight
1 Healthcare 25.3%
2 Technology 23.37%
3 Consumer Discretionary 18.23%
4 Industrials 16.77%
5 Communication Services 6.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
S icon
51
SentinelOne
S
$7.26B
$29.8M 0.45%
+701,000
New +$29.8M
KALV
52
DELISTED
KalVista Pharmaceuticals
KALV
$28.5M 0.43%
1,191,101
+231,209
+24% +$6.05M
SOFI icon
53
PUT
SoFi Technologies
SOFI
$24.4B
$27.6M 0.41%
1,440,000
-310,000
-18% -$5.75M
MREO
54
Mereo BioPharma
MREO
$46.4M
$27.4M 0.41%
8,649,300
+2,283,800
+36% +$7.66M
BGRY
55
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
$24.9M 0.37%
2,500,708
+708
+0% +$7.08K
MRTX
56
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$24M 0.36%
+148,872
New +$23.9M
DCPH
57
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$23.9M 0.36%
652,635
+315,827
+94% +$12.2M
HRTX icon
58
Heron Therapeutics
HRTX
$60.4M
$23.1M 0.35%
1,490,440
+984,403
+195% +$15.7M
AMAM
59
DELISTED
Ambrx Biopharma Inc
AMAM
$22.9M 0.34%
+1,169,529
New +$19.9M
SLDB icon
60
Solid Biosciences
SLDB
$997M
$21.9M 0.33%
398,280
– –
PNT
61
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$21M 0.31%
2,045,600
+969,600
+90% +$9.86M
AGC
62
DELISTED
Altimeter Growth Corp
AGC
$20.5M 0.31%
+1,753,264
New +$21.5M
FTCV
63
DELISTED
FinTech Acquisition Corp. V Class A Common Stock
FTCV
$20.3M 0.3%
+1,661,845
New +$19.2M
FBRX icon
64
Forte Biosciences
FBRX
$1.63B
$17.4M 0.26%
20,678
-3,322
-14% -$2.99M
FULC icon
65
Fulcrum Therapeutics
FULC
$292M
$17.1M 0.26%
1,627,444
+101,559
+7% +$1.03M
RXDX
66
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$15.4M 0.23%
625,625
+47,091
+8% +$1.05M
SIOX
67
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$15M 0.22%
5,489,000
– –
BOLT icon
68
Bolt Biotherapeutics
BOLT
$7.07M
$14.8M 0.22%
47,704
+26,686
+127% +$10.8M
SYRE icon
69
Spyre Therapeutics
SYRE
$9.39B
$14.6M 0.22%
83,764
+29,081
+53% +$5.28M
MQ icon
70
Marqeta
MQ
$1.7B
$14.1M 0.21%
+125,975
New +$15M
IRON icon
71
Disc Medicine
IRON
$3.06B
$13.8M 0.21%
71,167
+27,422
+63% +$9.02M
TERN
72
DELISTED
Terns Pharmaceuticals
TERN
$13.8M 0.21%
1,125,136
– –
KDNY
73
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$13.7M 0.2%
968,023
+418,408
+76% +$6.69M
OWL icon
74
Blue Owl Capital
OWL
$18.2B
$12.9M 0.19%
+1,000,000
New +$11.3M
INSM icon
75
Insmed
INSM
$27.5B
$12.6M 0.19%
+441,065
New +$13.1M
1 2
3
4 5

Similar funds

NC
Nicholas Company Milwaukee, Wisconsin $5.47B AUM 16.96% 1-Year Est. Return
EI
EFG International Zurich $5.46B AUM
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
ENV
Exor N.V. Amsterdam, Netherlands $5.46B AUM 6.21% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
VCM
Voleon Capital Management Berkeley, California $5.49B AUM 56.94% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
TPCW
TD Private Client Wealth New York $5.44B AUM 18.56% 1-Year Est. Return

Aaron Cowen's Q2 2021 Portfolio in Review

As of Q2 2021, Aaron Cowen held 142 positions worth $6.69B, down 1.1% from $6.76B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Aaron Cowen withdrew a net $285M in Q2 2021, closing 20 positions and reducing 23 holdings. Its most notable exit was McDonald's, an estimated $214M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Aaron Cowen opened a new position in Alphabet (Google) Class C worth $269M.

  • Aaron Cowen's largest Q2 2021 buy was Alphabet (Google) Class C: 2,143,380 shares worth $269M.
  • Aaron Cowen added most to Amazon in Q2 2021, an estimated $88.8M increase.
  • Aaron Cowen's biggest Q2 2021 reduction was Five Below, cutting an estimated $147M.
  • Aaron Cowen fully exited McDonald's in Q2 2021, selling an estimated $214M.
  • Aaron Cowen's ten largest holdings make up 38% of its $6.69B portfolio in Q2 2021.
  • Aaron Cowen opened 36 new positions and closed 20 in Q2 2021.
  • Aaron Cowen's portfolio value fell 1.1% quarter-over-quarter to $6.69B.

Based on Suvretta Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.